The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular DystrophyFrancesco Muntoni, Alberto Dubrovsky, Brenda Wong et al.|Neurology and Therapy|2024Cited by 23
614PCANYON trial results: sevasemten, an investigational fast skeletal myosin inhibitor, reduced muscle damage biomarkers and stabilized function in BMDC. McDonald, J. Donovan, H. Kushlaf et al.|Neuromuscular Disorders|2025Cited by 0